Reporter brief
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS): Randomized, Placebo-controlled Pilot Study.
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Without reported outcomes or effect sizes, this abstract does not demonstrate whether metformin is safe, tolerable, or neuroprotective in this population
- Sample size is not reported, making it impossible to assess statistical power or generalizability
- This is a pilot study; findings cannot be generalized to broader populations of older adults with MS
Study design and sample
Rct; Human.
Older people with multiple sclerosis (MS)
- Design
- Rct
- Sample
- —
- Journal
- State University of New York at Buffalo
- Published
- Nov 21, 2025
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.